AMGN vs CRL: fair value comparison
Amgen Inc. and Charles River Laboratories International, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CRL currently sits closer to the top of our discount ranking. AMGN carries the stronger quality grade.
| AMGN | CRL | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $432.42 | $291.50 |
| 12-month range | $286.92–$385.70 | $161.25–$232.51 |
| Sector rank | #104 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | B | C |
| Momentum grade | C | — |
| Leverage | High | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · CRL fair value analysis